Mission: Our Vision
We are leaders in utilizing the innate immune system on behalf of patients to address unmet clinical needs. We are committed to a rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the ...
BERKELEY, Calif. – April 18 2016 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B
Dynavax Reports Top Line Results of Phase 3 HEPLISAV-B(TM) Study
A collaborative and inspiring place to thrive where you can make a difference
Join the dynamic team at Dynavax focused on innovative sciences to make a difference in the lives of patients. Our employees come from diverse backgrounds and thrive in our collaborative, inspiring, and fast-paced environment. We create a work setting that motivates, is enjoyable and rewarding. We welcome you to join our team!
We are committed to utilizing the immune system to prevent and fight disease.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.
HEPLISAV-B™ - Our Lead Product Candidate
HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.
SD-101 - Cancer Immunotherapy
We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.
TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma.
Dynavax Technologies is proud to offer comprehensive and highly competitive benefits to our employees and their families. From health care and financial benefits, to time off and employee services, our benefits help support our employees’ needs now and in the future.
I worked at Dynavax Technologies full-time (Less than a year)
Wonderful people to work with and exciting future of the company.
Market rate compensation for all employees.
Unprofessional disorganized and downright rude Draconian
And disgusting. They put a job description which was vague and written for them to gauge the applicants they would get accordingly. It took over a year for them to get a phone screen going . The Human Resources person was completely disrespectful and said the interview was with one person it was not . It was a panel and it was completely disorganized and insulting . They did not read it and they also kept mentioning I worked at a company which I never had. They didn't bother to ask if I can hear them or hey sorry this is a panel. The director is a joke and a complete air head